Marijuana stocks have gone through a massive roller-coaster ride over the past couple of years. Go back to 2018, and it seemed that even the tiniest companies with ties to cannabis were soaring, even if their business models were unproven. Now, there's just as much pessimism as there was optimism back then, and even well-established leaders in the cannabis industry have felt the pain.

A poll by Goldbeck Recruiting Inc. indicates that stigma and personal bias may play bigger roles in the potential of the cannabis industry in Canada than previously thought.

Results reflect input from 1,521 members of the Angus Reid Forum, an online public opinion community in which people across Canada answer surveys on various topics in exchange for points that can be redeemed for prizes or rewards.

Goldbeck gleaned data from the polls in creating its 2020 Cannabis Labour Market report, which explores why job-seekers are willing (or not willing) to work in the cannabis industry.

The Coronavirus has swept its way across the market over the past month. In that time, world markets have declined to lower levels. But with this massive selloff comes the opportunity to find potentially lucrative marijuana stocks to buy at lower prices than usual. For those not privy to the MSO market, these marijuana stocks have managed to make continual gains while others have failed. MSO or multi-state operator pot stocks work by owning retail dispensaries around various states in the U.S. Because of their role in the retail market, they are not nearly as subject to the volatility of pure-play pot stocks.

The purpose of due diligence is to reduce risk when entering into an agreement or contract with another party. While it may seem like a pain, the due diligence process is a normal and necessary part of any investment or M&A transaction.

However, there are a few prominent challenges cannabis businesses and their prospective investors or partners encounter when going through the process — mostly due to the unique nature of the cannabis industry.

To illuminate some of the specific challenges cannabis operators face, here are five questions that a potential investor or partner could ask as part of the due diligence process: 

Due to coronavirus panic buys, toilet paper shortages are being reported across North America. While retailers try to put limits on the number of packages its customers can buy, one enterprising Canadian cannabis company is taking advantage of the situation for a noble purpose.

TVAPE, an Ontario-based retailer of cannabis vaporizers, is promising to ship coveted stock to nearby locations. But all is not exactly as it seems. Originally listed at a steep $130 per roll (a supposedly marked down rate from a previous listing of $270), the product is now “out of stock.”

It turns out that TVAPE isn’t actually selling toilet paper. Instead, the company is using the hysteria surrounding stockpiling essential supplies to raise awareness of Covid-19.

What happened

Shares of Aurora Cannabis (NYSE:ACB) were up 3.4% as of 11:26 a.m. EDT on Tuesday after rising as much as 12.6% earlier in the day. The Canadian cannabis producer didn't have any news of its own. Instead, today's move is part of an overall rebound for the stock market after Monday's massive sell-off.

Cannabis infused beverages is an area of major interest for companies, investors and consumers, and is a vertical that we have been focused on.

Although this has been area of interest for companies, there are a limited number of cannabis infused beverages that are on the market and this is a trend that our readers should be aware of. The lack of products on the market implies that there is a significant opportunity for companies with an MVP (minimum viable product) ready to go to market.

Pot stocks have had better days, to say the least. Well, this sentiment can be shared amongst the entire stock market. With several issues currently plaguing stock prices, what in specific is causing marijuana stocks to drop so heavily in value? Well for starters, issues surrounding the Coronavirus have led the entire world market to see the worst declines in value in over ten years.

Strong cash positions and the ability to negotiate with suppliers will be key for cannabis companies looking to withstand any operational disruption caused by COVID-19, according to one leading cannabis analyst.

Eight Capital’s Graeme Kreindler wrote in a report Monday that the rise of coronavirus cases globally is likely to see the cannabis sector in North America face the supply chain pressures that other industries are already facing – mainly sourcing items from China and finding protective gear.

Pot stocks were hammered in 2019. Nearly every company lost at least 50% of its value. Cannabis demand, on the other hand, continues to climb. This disconnect provides patient investors a clear path to profit.

As with any early-stage market, investors scrambled at the chance to inject pent-up capital into cannabis companies. In 2018, many pot stocks rose by more than 1,000%. By 2019, the hype bubble had popped, sending short-term investors to the sidelines.

Pot stocks were overvalued in 2018, but there’s an argument that the pendulum has swung too far the other way. It doesn’t take a mathematician to realize that many cannabis producers are trading at bargain valuations.